Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NASDAQ:DFTX NYSE:HIMS NYSE:PACS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$142.53+1.6%$120.05$10.26▼$151.02$6.95B0.09835,787 shs660,709 shsDFTXDefinium Therapeutics$22.65+8.5%$20.61$6.34▼$26.25$2.26B2.371.82 million shs2.11 million shsHIMSHims & Hers Health$23.98+4.1%$24.07$13.74▼$70.43$5.47B2.4332.64 million shs15.04 million shsPACSPACS Group$37.72+1.9%$34.44$7.50▼$43.08$5.97B-0.03949,083 shs928,590 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+7.06%+12.75%+16.86%+31.43%+1,217.75%DFTXDefinium Therapeutics+4.25%-5.18%-9.97%+20.85%+174.61%HIMSHims & Hers Health+2.64%-4.35%-25.63%+45.67%-62.33%PACSPACS Group+0.31%-10.22%+2.60%-4.26%+250.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$142.53+1.6%$120.05$10.26▼$151.02$6.95B0.09835,787 shs660,709 shsDFTXDefinium Therapeutics$22.65+8.5%$20.61$6.34▼$26.25$2.26B2.371.82 million shs2.11 million shsHIMSHims & Hers Health$23.98+4.1%$24.07$13.74▼$70.43$5.47B2.4332.64 million shs15.04 million shsPACSPACS Group$37.72+1.9%$34.44$7.50▼$43.08$5.97B-0.03949,083 shs928,590 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+7.06%+12.75%+16.86%+31.43%+1,217.75%DFTXDefinium Therapeutics+4.25%-5.18%-9.97%+20.85%+174.61%HIMSHims & Hers Health+2.64%-4.35%-25.63%+45.67%-62.33%PACSPACS Group+0.31%-10.22%+2.60%-4.26%+250.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 2.83Moderate Buy$149.305.20% UpsideDFTXDefinium Therapeutics 3.00Buy$37.9269.00% UpsideHIMSHims & Hers Health 2.12Hold$29.3724.06% UpsidePACSPACS Group 2.71Moderate Buy$48.0030.62% UpsideCurrent Analyst Ratings BreakdownLatest DFTX, CELC, PACS, and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026CELCCelcuity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/19/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$30.00 ➝ $28.005/18/2026PACSPACS Group Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $52.005/18/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.005/15/2026CELCCelcuity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$150.00 ➝ $183.005/15/2026CELCCelcuity Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$157.005/14/2026PACSPACS Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026PACSPACS Group OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $48.005/13/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$32.00 ➝ $30.005/12/2026HIMSHims & Hers Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)5/12/2026HIMSHims & Hers Health Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.50(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$1.10 per shareN/ADFTXDefinium TherapeuticsN/AN/AN/AN/A$2.80 per shareN/AHIMSHims & Hers Health$2.37B2.28$0.88 per share26.81$1.96 per share12.08PACSPACS Group$5.29B1.10$1.60 per share22.97$6.58 per share5.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$177.04M-$3.90N/A3,547.85N/AN/A-244.61%-50.22%N/ADFTXDefinium Therapeutics-$183.79M-$2.49N/AN/AN/AN/A-100.30%-69.22%N/AHIMSHims & Hers Health$128.37M-$0.09N/A48.3139.59-0.56%6.10%1.52%N/APACSPACS Group$191.54M$1.5623.5615.061.124.49%26.47%4.36%N/ALatest DFTX, CELC, PACS, and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CELCCelcuity-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/11/2026Q1 2026PACSPACS Group$0.42$0.50+$0.08$0.50$1.36 billion$1.42 billion5/8/2026Q1 2026DFTXDefinium Therapeutics-$0.4780-$0.71-$0.2320-$0.71N/AN/A3/25/2026Q4 2025CELCCelcuity-$1.06-$0.97+$0.09-$0.97$1.28 millionN/A2/23/2026Q4 2025HIMSHims & Hers Health$0.02$0.08+$0.06$0.08$619.48 million$617.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/ADFTXDefinium TherapeuticsN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity6.0412.3112.31DFTXDefinium Therapeutics0.154.694.69HIMSHims & Hers Health2.181.691.56PACSPACS Group0.270.990.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%DFTXDefinium Therapeutics27.91%HIMSHims & Hers Health63.52%PACSPACS GroupN/AInsider OwnershipCompanyInsider OwnershipCELCCelcuity13.33%DFTXDefinium Therapeutics2.26%HIMSHims & Hers Health11.76%PACSPACS Group70.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4048.77 million42.27 millionOptionableDFTXDefinium Therapeutics4099.70 million97.45 millionOptionableHIMSHims & Hers Health2,442227.94 million201.13 millionOptionablePACSPACS Group47,455158.27 million47.32 millionOptionableDFTX, CELC, PACS, and HIMS HeadlinesRecent News About These CompaniesJohn Todd Mitchell Sells 27,389 Shares of PACS Group (NYSE:PACS) StockMay 21 at 5:01 AM | americanbankingnews.comJohn Todd Mitchell Sells 52,763 Shares of PACS Group (NYSE:PACS) StockMay 21 at 5:01 AM | americanbankingnews.comUBS Group AG Sells 175,803 Shares of PACS Group, Inc. $PACSMay 21 at 3:53 AM | marketbeat.comInsider Selling: PACS Group (NYSE:PACS) Insider Sells 27,389 Shares of StockMay 20 at 5:50 AM | insidertrades.comPACS Group's (NYSE:PACS) Performance Is Even Better Than Its Earnings SuggestMay 18 at 1:04 PM | finance.yahoo.comPACS Group, Inc. (NYSE:PACS) Receives Consensus Recommendation of "Buy" from AnalystsMay 16, 2026 | americanbankingnews.comPACS Group (PACS) Is Up 22.1% After Q1 Beat, Guidance Hike and Buyback LaunchMay 14, 2026 | finance.yahoo.comPACS Group Q1 Earnings Call HighlightsMay 14, 2026 | marketbeat.comPACS Group: Strong Comeback That's Backed By Improving FundamentalsMay 13, 2026 | seekingalpha.comWhy PACS Group Stock Surged TodayMay 12, 2026 | fool.comPACS Group, Inc. (PACS) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comPACS Group, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comPACS Group, Inc. (PACS) Q1 Earnings and Revenues Surpass EstimatesMay 11, 2026 | zacks.comPACS Group, Inc. Reports First Quarter 2026 ResultsMay 11, 2026 | businesswire.comPACS vs. MEDP: Which Stock Is the Better Value Option?May 11, 2026 | zacks.comPACS Group, Inc. $PACS Stake Increased by Vanguard Group Inc.May 11, 2026 | marketbeat.comHead-To-Head Analysis: Beauty Health (NASDAQ:SKIN) vs. PACS Group (NYSE:PACS)May 11, 2026 | americanbankingnews.comPACS Group (NYSE:PACS) Raised to "Buy" at Wall Street ZenMay 10, 2026 | marketbeat.comPACS Group Inc (PACS) Q1 2026 Earnings Report Preview: What To ExpectMay 8, 2026 | finance.yahoo.comPACS Group Intends to Release First Quarter 2026 Earnings on Monday, May 11, 2026, and Host a Call to Discuss Financial Results on Tuesday, May 12, 2026May 5, 2026 | businesswire.comA new class of super PACs is emerging. Voters are wary.May 5, 2026 | politico.comPNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026DFTX, CELC, PACS, and HIMS Company DescriptionsCelcuity NASDAQ:CELC$142.53 +2.19 (+1.56%) Closing price 04:00 PM EasternExtended Trading$142.74 +0.22 (+0.15%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Definium Therapeutics NASDAQ:DFTX$22.65 +1.78 (+8.53%) As of 04:00 PM EasternMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Hims & Hers Health NYSE:HIMS$23.98 +0.94 (+4.08%) Closing price 03:59 PM EasternExtended Trading$24.06 +0.08 (+0.33%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.PACS Group NYSE:PACS$37.72 +0.72 (+1.95%) Closing price 03:59 PM EasternExtended Trading$37.70 -0.02 (-0.07%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
